Hermay Labs Corporation is a chemistry-based scientific laboratory dedicated to cutting-edge research and development. It was founded in 2019 by Dr. John Yao. Dr. Yao is a devoted scientist and entrepreneur who collaborates with partners and clients to develop innovative technologies and products that improve human health and the environment.
Hermay Labs is home to a team of skilled scientists with expertise in synthetic chemistry, medicinal chemistry, computational chemistry, and biochemistry. We are proud to have a healthy and supportive corporate culture whose core values include honesty, integrity, and innovation. We maintain our clients' trust through our high-equality research, quick delivery, exceptional value-added services, and competitive prices.
Hermay Labs Corporation is one of the leading Contract Research Organizations (CRO) in Canada. Its core areas of expertise are organic synthesis and medicinal chemistry. The leadership team has over 30 years of synthetic, medicinal chemistry, and CRO experience with a strong record of successfully executing projects for industry and academic institutions.
The company is based in scenic Edmonton, Alberta, Canada, and operates out of a 10,000 square foot laboratory area in Edmonton Research Park, with the capability to synthesize complex chemical compounds in quantities ranging from micrograms to kilograms.
Hermay Labs has expanded its services areas from synthetic chemistry to computer assisted drug discovery and development, cell-based assays, proteomics, drug delivery, and formulation. We are currently collaborating with partners to establish a facility for kg scale API GMP manufacturing.
Custom satisfaction as our highest priority. We will do our best to provide outstanding services and products. Please feel free to contact us at firstname.lastname@example.org
Dr. John Yao is an experienced scientist and entrepreneur. He has more than 30 years of experience in new drug development, chemical synthesis and operational management. Dr. Yao has founded and co-founded several companies ranging from contract research organization (CRO) to innovative drug discovery and development companies.
Dr. Wiebe is a seasoned medicinal chemist and an Adjunct Professor & Professor Emeritus in Department of Oncology, Faculty of Medicine & Dentistry at University of Alberta. Dr. Wiebe is the inventor of the widely used clinical PET imaging agent FAZA. Dr. Wiebe held research appointments at the University of Tübingen, the German Cancer Research Center, and Heidelberg University in Germany, and the Royal Prince Alfred Hospital and Sydney University in Australia. He has served as an expert consultant to numerous Universities and international agencies, including the Volkswagen Foundation, Cancer UK, the Helmholtz Foundation, and the Canadian Institutes for Health Research. Dr. Wiebe was the Alexander von Humboldt Foundation's first Ambassador Scientist for Canada (2007-2012) and the first permanent Director of Biomedicine and Health at ANSTO. He is a member of the Editorial Boards of several international scientific journals published in his fields of interest.
Dr. Hall is a Professor in the Department of Chemistry at the Faculty of Science, University of Alberta. He is an elected Fellow of the Royal Society of Canada and Canada Research Chair in Boron Chemistry for Catalysis and Drug Discovery. Dr. Hall was recognized with the award of the prestigious Killam Research Fellowship from the Canada Council for the Arts; one of only six awarded annually across the country in the fields of arts, science, and engineering.
Dr. Ling is a Professor in the department of Chemistry at University of Calgary. He is an expert in carbohydrate chemistry and bioorganic chemistry. His research applied modern synthetic carbohydrate chemistry and bioorganic chemistry to the understanding of carbohydrate-protein interactions involved in tumorigenesis, cancer metastasis and infection, and to the design, synthesis and immunological evaluation of microbial and tumor-associated mammalian carbohydrate antigens. Dr. Ling’s research team designed and synthesized inhibitors that selectively interfering with the crucial biosynthetic pathways that cancer cells rely on to survive, spread and proliferate and to raise antibodies with high immune specificity and immunoaffinity to prevent infectious disease.